BrainStorm Cell Therapeutics Inc. Expands Pipeline with the Initiation of a Study for Multiple Sclerosis
Published: Mar 12, 2012
NEW YORK & PETACH TIKVAH, ISRAEL--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a developer of adult stem cell technologies and CNS therapeutics, announces plans to initiate a preclinical study assessing the efficacy of its NurOwn™ stem cell technology in patients with Multiple Sclerosis (MS). Positive proof-of-concept results for MS have been confirmed in a set of in-vitro and in-vivo experiments, and the Company is working to advance MS into preclinical development in Q2 2012.